Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

Oligodendrogliomas Clinical Trial

Official title:

Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00213876
• Other study ID #: 3154
• Status: Completed
• Phase: N/A
• First received: September 13, 2005
• Last updated: August 29, 2011
• Start date: February 2004
• Est. completion date: August 2011

Study information

• Verified date: August 2011
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 189
• Est. completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• Paediatric and adult patients (> 1 year of age)

• Patient with oligodendroglioma or medulloblastoma or glioma

• Possibility of 3 year follow-up

• Patient consent obtained

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Oligodendroglioma
• Oligodendrogliomas

Locations

Country	Name	City	State
France	Natacha Entz-Werle	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France,